Skip to Content
  • PARP Inhibitors Do It Again

    When we last looked in on the long-running saga of PARP inhibitors around here, Tesaro had posted excellent clinical results for their compound and re-invigorat… Read More
  • The Coming Landscape?

    Adam Feuerstein has an important list of companies (the “Gnarly Nine”) that will be going to the FDA soon. That process is always important for the… Read More
  • Gene Therapy Needs Machines

    News came recently of an apparent cure, via gene therapy, of sickle-cell disease in a young patient (whose condition was refractory to hydroxyurea and the other… Read More
  • Nativis Lives the Life

    I sort of hate to bring them up again, but a reader sent along this link to a story at Geekwire, all about how there’s a Seattle company has raised $10 mi… Read More
  • Are Phase I Trials Ethical?

    It’s been a year since the clinical trial disaster in France that led to several participants being hospitalized with brain damage. Back in November, the… Read More
  • Vivek Ramaswamy’s Plans

    I last wrote about Vivek Ramaswamy in the context of his first company (Axovant). That one went public on the hopes for a retread Alzheimer’s drug to wor… Read More
Page 1 of 4312345...102030...Last »